MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co EBIT per Share

The EBIT per Share of MicroTech Medical (Hangzhou) Co (2235.HK) as of Oct 27, 2026 is 0.13 CNY. In the previous year, EBIT per Share was -0.15 CNY — a change of -190.64% (higher).

EBIT per Share

0.13CNY

YoY

-190.64%

Last updated:

EBIT per Share of MicroTech Medical (Hangzhou) Co is 2025 0.13 CNY. EBIT per Share of MicroTech Medical (Hangzhou) Co was 2024 -0.15 CNY. It decreases by -190.64% higher compared to the previous year.

The MicroTech Medical (Hangzhou) Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
-0.18 CNY
Jan 1, 2022
-0.08 CNY
Jan 1, 2023
-0.28 CNY
Jan 1, 2024
-0.15 CNY
Jan 1, 2025
0.13 CNY
Jan 1, 2026 (e)
0.28 CNY
Jan 1, 2027 (e)
0.51 CNY
Jan 1, 2028 (e)
0.70 CNY
The MicroTech Medical (Hangzhou) Co EBIT per Share history
YEAREBIT per ShareYoY
est0.70CNY+37.07%
est0.51CNY+79.02%
est0.28CNY+112.47%
0.13CNY-190.64%
-0.15CNY-47.66%
-0.28CNY+239.49%
-0.08CNY-54.10%
-0.18CNY-54.97%
-0.40CNY+75.80%
-0.23CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

EBIT per Share of MicroTech Medical (Hangzhou) Co is 0.13 CNY in 2025.

EBIT per Share of MicroTech Medical (Hangzhou) Co changed from -0.15 CNY to 0.13 CNY, representing a -190.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co